The stock of Prothena Corporation PLC (NASDAQ:PRTA) is a huge mover today! The stock increased 5.54% or $3.32 on November 23, hitting $63.23. About 588,835 shares traded hands or 35.06% up from the average. Prothena Corporation PLC (NASDAQ:PRTA) has risen 31.46% since April 22, 2016 and is uptrending. It has outperformed by 26.05% the S&P500.
The move comes after 9 months positive chart setup for the $2.00B company. It was reported on Nov, 24 by Barchart.com. We have $67.66 PT which if reached, will make NASDAQ:PRTA worth $140.00M more.
Analysts await Prothena Corporation PLC (NASDAQ:PRTA) to report earnings on February, 16. They expect $-1.21 EPS, down 59.21% or $0.45 from last year’s $-0.76 per share. After $-1.26 actual EPS reported by Prothena Corporation PLC for the previous quarter, Wall Street now forecasts -3.97% EPS growth.
Prothena Corporation PLC (NASDAQ:PRTA) Ratings Coverage
Out of 5 analysts covering Prothena Corp (NASDAQ:PRTA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Prothena Corp has been the topic of 10 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Wedbush maintained it with “Outperform” rating and $81 target price in Tuesday, August 4 report. Deutsche Bank initiated Prothena Corporation PLC (NASDAQ:PRTA) on Thursday, November 3 with “Buy” rating. Wedbush maintained the shares of PRTA in a report on Friday, February 19 with “Outperform” rating. The stock of Prothena Corporation PLC (NASDAQ:PRTA) earned “Overweight” rating by Barclays Capital on Friday, May 13. The rating was maintained by Barclays Capital with “Overweight” on Thursday, August 4. Credit Suisse initiated the stock with “Outperform” rating in Thursday, January 21 report. The stock of Prothena Corporation PLC (NASDAQ:PRTA) earned “Outperform” rating by RBC Capital Markets on Thursday, November 19.
According to Zacks Investment Research, “Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson’s disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer’s disease. Prothena Corporation plc is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.19, from 1.04 in 2016Q1. The ratio improved, as 13 funds sold all Prothena Corporation PLC shares owned while 40 reduced positions. 11 funds bought stakes while 44 increased positions. They now own 23.97 million shares or 13.54% less from 27.72 million shares in 2016Q1.
Shinko Asset Ltd owns 19,040 shares or 0% of their US portfolio. Winslow Evans & Crocker Inc last reported 0% of its portfolio in the stock. Bessemer Gp last reported 35 shares in the company. Cupps Mgmt Ltd Limited Liability Company last reported 16,915 shares in the company. Brick Kyle accumulated 0% or 15 shares. Westfield Mngmt Communications L P owns 237,880 shares or 0.07% of their US portfolio. Teacher Retirement System Of Texas has 4,021 shares for 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 709 shares. Blackrock Institutional Tru Na has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Thompson Siegel & Walmsley Ltd Liability last reported 21 shares in the company. Intll Group accumulated 19,995 shares or 0% of the stock. Camarda Advisors Ltd Liability Corporation holds 12 shares or 0% of its portfolio. Ubs Oconnor Ltd Liability Corporation holds 0% or 28,380 shares in its portfolio. The United Kingdom-based Gsa Ptnrs Ltd Liability Partnership has invested 0.02% in Prothena Corporation PLC (NASDAQ:PRTA). Goldman Sachs Gru holds 0% or 70,418 shares in its portfolio.
Insider Transactions: Since July 20, 2016, the stock had 0 buys, and 8 insider sales for $3.70 million net activity. 5,000 shares with value of $271,173 were sold by Walker Karin L on Thursday, October 13. The insider HOMAN ARTHUR W sold 3,125 shares worth $162,991. Selkoe Dennis J. had sold 5,000 shares worth $273,076 on Monday, August 22. Kinney Gene G. sold $472,905 worth of stock.
More news for Prothena Corporation PLC (NASDAQ:PRTA) were recently published by: Marketwatch.com, which released: “Virtual Stock Exchange” on April 02, 2013. Fool.com‘s article titled: “Why Prothena Corporation Plc is Soaring Higher Today” and published on March 20, 2015 is yet another important article.
PRTA Company Profile
Prothena Corporation Public Limited Company, incorporated on September 26, 2012, is a global biotechnology company. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003). The Firm has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.